In longevity science circles, few topics generate more excitement — or more debate — than nicotinamide adenine dinucleotide (NAD+) and its precursors. Harvard professor David Sinclair has publicly discussed taking NMN as part of his personal anti-aging protocol. Researchers at Washington University School of Medicine have published human clinical trials on NMN supplementation. The global NAD+ supplement market has surpassed $400 million annually and is growing rapidly.
But what does the evidence actually support? And is this a genuine breakthrough in aging biology or another overhyped supplement trend?
The answer, unusually for this genre of question, is genuinely nuanced — because the underlying biology is real, the preclinical evidence is compelling, and the human clinical trial data, while still early, is beginning to validate some of the mechanisms that have excited researchers for two decades.
What Is NAD+ and Why Does It Decline With Age?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the body, functioning as a critical electron carrier in metabolic reactions and as a substrate for multiple classes of enzymes with roles in DNA repair, gene expression regulation, and cellular stress response.
Its most important enzymatic roles include:
Sirtuins (SIRT1–7): A family of longevity-associated deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammation — all processes central to the aging phenotype. Sirtuins are NAD+-dependent; they cannot function without adequate NAD+ as a co-substrate. David Sinclair's "information theory of aging" places sirtuin dysregulation — driven by declining NAD+ — at the center of the aging process.
PARP enzymes (Poly-ADP ribose polymerases): DNA damage repair enzymes that consume NAD+ as a substrate. As DNA damage accumulates with age (from radiation, oxidative stress, and metabolic byproducts), PARP activation increases, further depleting the NAD+ pool in a cycle that impairs both repair and sirtuin function simultaneously.
CD38: An enzyme that degrades NAD+ and whose activity increases dramatically with aging and chronic inflammation — one of the primary drivers of the 40–60% decline in tissue NAD+ levels documented between young adulthood and midlife in human and animal studies.
The consequence of NAD+ decline: impaired mitochondrial function, reduced cellular energy production, accumulated DNA damage, dysregulated gene expression, and increased cellular senescence — collectively, the hallmarks of biological aging.
NMN vs NR: The Two Primary NAD+ Precursors
The supplement market offers two primary NAD+ precursors:
NMN (Nicotinamide Mononucleotide): A direct precursor to NAD+ that enters cells via specific transporters (the Slc12a8 transporter, discovered by Shin-ichiro Imai's lab at Washington University) and is converted to NAD+ through a single enzymatic step. NMN is what David Sinclair takes and studies.
NR (Nicotinamide Riboside): An alternative NAD+ precursor that must be converted to NMN before entering the NAD+ synthesis pathway. NR has more published human clinical trial data than NMN (primarily from ChromaDex, who holds key NR patents under the Tru Niagen brand) but the additional conversion step makes it marginally less direct.
Both compounds raise blood and tissue NAD+ levels in humans — this is the best-established finding in the human clinical literature. The more important question is whether raising NAD+ via oral supplementation actually produces the functional benefits observed in animal models.
What Human Clinical Trials Show
NAD+ elevation confirmed: Multiple Phase 1 and Phase 2 trials in humans confirm that both NMN (250–1,000mg/day) and NR (300–1,000mg/day) significantly raise blood NAD+ levels — typically by 40–90% above baseline within 2–4 weeks of daily supplementation. This is a genuine, replicable finding.
Muscle function and insulin sensitivity: A 2021 Washington University double-blind RCT found that postmenopausal women with prediabetes who took 250mg NMN daily for 10 weeks showed improved skeletal muscle insulin signaling and glucose disposal compared to placebo — the first human evidence that NMN supplementation produces a meaningful metabolic benefit. The effect was specific to skeletal muscle and did not extend to liver or adipose tissue at this dose.
Exercise performance and muscle metabolism: A 2022 Japanese RCT found that NMN supplementation (250mg/day for 12 weeks) improved aerobic capacity measured by VO2 max and reduced levels of muscle fatigue-related blood markers in amateur runners — suggesting genuine exercise performance benefits through improved mitochondrial function.
Cognitive function: Preliminary evidence from small trials suggests NMN and NR supplementation may improve cognitive performance in older adults, potentially through improved cerebral blood flow and neuronal NAD+ metabolism. These findings require larger replication.
Cardiovascular health: NR supplementation has shown reductions in blood pressure and arterial stiffness in early clinical trials — effects consistent with improved vascular NAD+ biology.
What Remains Unproven in Humans
The dramatic longevity extensions, physical function restoration, and anti-aging effects observed in mouse models have not been replicated in human trials — because human trials at the scale and duration required to demonstrate lifespan extension do not yet exist. The preclinical data is genuinely compelling, but extrapolating mouse aging studies to humans requires enormous caution.
Current human evidence supports: metabolic benefits (insulin sensitivity, glucose disposal), modest exercise performance improvements, and cardiovascular health markers. It does not yet confirm reversal of aging phenotypes, dramatic functional restoration, or lifespan extension in humans.
Practical Protocol
Dose: 250–500mg NMN daily is the range with the most human clinical evidence. Higher doses (750–1,000mg) are used in some protocols but without proportionally stronger human data at present.
Timing: Morning consumption may align better with circadian NAD+ metabolism — NAD+ and sirtuin activity follow circadian rhythms, and morning supplementation may better support daytime metabolic functions.
Sublingual or liposomal forms: Standard NMN capsules have limited oral bioavailability due to intestinal degradation. Sublingual powders and liposomal formulations show superior blood NAD+ elevation in preliminary comparisons.
Combination with resveratrol: David Sinclair's personal protocol includes NMN + resveratrol + metformin, based on the theoretical synergy between NAD+ elevation (activating sirtuins) and resveratrol (activating SIRT1 directly). Human evidence for this specific combination remains preliminary.
Quality verification: NAD+ precursor supplement quality varies significantly. Third-party tested products with certificate of analysis confirming NMN purity and stability are essential — the compound degrades in heat and moisture, and many products do not survive storage conditions intact.
Who Benefits Most
NMN and NR supplementation appears most relevant for adults over 40, where NAD+ decline is most pronounced; people with metabolic dysfunction or insulin resistance; endurance athletes seeking mitochondrial optimization; and individuals with strong longevity motivation willing to invest in an emerging science. Younger adults with no metabolic dysfunction have less clear rationale for supplementation at current evidence levels.
The Bottom Line
NAD+ precursor supplementation — particularly NMN and NR — represents one of the most scientifically grounded interventions in the emerging longevity supplement space. The biology is real, the NAD+-elevating effects in humans are confirmed, and early clinical trials show genuine metabolic and exercise performance benefits. The transformative anti-aging effects seen in animal models await replication at human scale. For adults over 40 motivated by longevity science, 250–500mg of high-quality NMN daily is among the most rationally supported supplement additions available — with the understanding that it is an investment in promising science, not yet proven clinical medicine.
